MOB.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Jun 2024 @ 03:15):

Stats
Today's Volume	119 422
Average Volume	698 654
Market Cap	727.56M
EPS	SEK0 ( 2024-05-14 )
Next earnings date	( SEK0 ) 2024-08-12
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-24.78
ATR14	SEK0.0670 (0.26%)

Volume Correlation

Long: 0.16 (neutral)

Short: -0.34 (neutral)

Signal:(56.523) Neutral

Moberg Pharma AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Moberg Pharma AB (publ) Correlation - Currency/Commodity

0.57
( weak )

0.68
( moderate )

0.00
( neutral )

0.54
( weak )

-0.66
( moderate negative )

Moberg Pharma AB (publ) Financials

Annual	2023
Revenue:	SEK0
Gross Profit:	SEK-2.10M (0.00 %)
EPS:	SEK-1.330

FY	2023
Revenue:	SEK0
Gross Profit:	SEK-2.10M (0.00 %)
EPS:	SEK-1.330

FY	2022
Revenue:	SEK207 000
Gross Profit:	SEK-2.38M (-1 147.34 %)
EPS:	SEK-1.380

FY	2021
Revenue:	SEK0.00
Gross Profit:	SEK0.00 (0.00 %)
EPS:	SEK0.238

Financial Reports:

No articles found.

Moberg Pharma AB (publ) Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Moberg Pharma AB (publ)

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.